更新于：2024-11-04
Pramipexole Dihydrochloride
盐酸普拉克索
更新于：2024-11-04
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构
分子式C10H20ClN3OS |
InChIKeyZTZQAWQFTIVKMU-KLXURFKVSA-N |
CAS号191217-81-9 |
关联
199
项与 盐酸普拉克索 相关的临床试验Precision Care for Major Depressive Disorder
Investigating the effectiveness of pramipexole on anhedonia in patients undergoing maintenance therapy by buprenorphine: randomized double blind placebo: controlled trial
Safety and Efficacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (OCD): Pilot, Randomized and Controlled Clinical Trial
100 项与 盐酸普拉克索 相关的临床结果
登录后查看更多信息
100 项与 盐酸普拉克索 相关的转化医学
登录后查看更多信息
100 项与 盐酸普拉克索 相关的专利（医药）
登录后查看更多信息
1,482
项与 盐酸普拉克索 相关的文献（医药）2024-12-01Molecular biology reports
Oxidative stress in Alzheimer’s disease: current knowledge of signaling pathways and therapeutics
Review
作者: Sharma, Prajjwal ; Singh, Sunil K ; Dhapola, Rishika ; Beura, Samir K ; HariKrishnaReddy, Dibbanti
Alzheimer's disease's pathophysiology is still a conundrum. Growing number of evidences have elucidated the involvement of oxidative stress in the pathology of AD rendering it a major target for therapeutic development. Reactive oxygen species (ROS) generated by altered mitochondrial function, dysregulated electron transport chain and other sources elevate aggregated Aβ and neurofibrillary tangles which further stimulating the production of ROS. Oxidative stress induced damage to lipids, proteins and DNA result in neuronal death which leads to AD. In addition, oxidative stress induces apoptosis that is triggered by the modulation of ERK1/2 and Nrf2 pathway followed by increased GSK-3β expression and decreased PP2A activity. Oxidative stress exaggerates disease condition by interfering with various signaling pathways like RCAN1, CREB/ERK, Nrf2, PP2A, NFκB and PI3K/Akt. Studies have reported the role of TNF-α in oxidative stress stimulation that has been regulated by drugs like etanercept increasing the level of anti-oxidants. Other drugs like pramipexole, memantine, carvedilol, and melatonin have been reported to activate CREB/RCAN1 and Nrf2 pathways. In line with this, epigallocatechin gallate and genistein also target Nrf2 and CREB pathway leading to activation of downstream pathways like ARE and Keap1 which ameliorate oxidative stress condition. Donepezil and resveratrol reduce oxidative stress and activate AMPK pathway along with PP2A activation thus promoting tau dephosphorylation and neuronal survival. This study describes in detail the role of oxidative stress in AD, major signaling pathways involving oxidative stress induced AD and drugs under development targeting these pathways which may aid in therapeutic advances for AD.
2024-11-01JOURNAL OF CHEMICAL NEUROANATOMY
Chronic pramipexole and rasagiline treatment enhances dendritic spine structural neuroplasticity in striatal and prefrontal cortex neurons of rats with bilateral intrastriatal 6-hydroxydopamine lesions
Article
作者: Boyzo Montes de Oca, Alfonso ; Bringas, María E ; Flores, Gonzalo ; Aceves, Jorge ; de Oca, Alfonso Boyzo Montes ; Bringas, María E. ; Tendilla-Beltrán, Hiram
Parkinson's disease manifests as neurological alterations within dendritic spines in the striatal and neocortical brain regions, where their functionality closely correlates with morphology. However, the impact of current pharmacotherapy on dendritic spine neuroplasticity, crucial for novel drug development in neurological and psychiatric disorders, remains unclear. This study investigated the effects of 6-OHDA intrastriatal bilateral lesions in male adult rats on behavior and dendritic spine neuroplasticity in striatal and cortical neurons. Furthermore, it evaluated the influence of chronic co-administration of pramipexole (PPX), a D3 receptor agonist, and rasagiline (Ras), a selective MAO-B inhibitor, on these alterations. Lesioned animals exhibited impaired balance behavior, with no improvement following PPX-Ras treatment. The 6-OHDA lesion decreased dendritic spine density in caudate putamen (CPU) spiny projection neurons (SPNs), a change unaffected by treatment, though PPX-Ras increased mushroom spines and reduced stubby spines in these neurons. In nucleus accumbens (NAcc) SPNs and prefrontal cortex layer 3 (PFC-3) pyramidal cells, dendritic spine density remained unaltered, but PPX-Ras decreased mushroom spines and increased bifurcated spines in the NAcc, while increasing mushroom spines and decreasing stubby spines in PFC-3 in lesioned rats. These findings emphasize the importance of dendritic spines as promising targets for innovative pharmacotherapies for Parkinson's disease.
2024-10-01Journal of sleep research
Transcutaneous electrical nerve stimulation in the management of restless legs syndrome symptoms: A single‐blind, parallel‐group clinical study
Article
作者: Aktaş, Kübra ; Ortaç, Emine Aygül ; Şanli, Zeynep Selcan ; Binokay, Hülya
Summary:
The aim of this study was to investigate the additional effect of transcutaneous electrical nerve stimulation (TENS) on the control of the symptoms of restless legs syndrome (RLS). A total of 46 randomly selected patients diagnosed with RLS were divided into two groups in a single‐blind study to either receive pramipexole (0.25 mg daily) plus 10 sessions of TENS or only pramipexole (0.25 mg daily) for 4 weeks. The severity of the symptoms was determined according to the International Restless Legs Syndrome Rating Scale (IRLSRS) and the Pittsburgh sleep quality index (PSQI) at the beginning of the treatment, post‐treatment, and at an 8 week follow‐up. A significant time interaction was observed between the groups for all measurement outcomes, revealing differences in favour of the experimental group's IRLSRS and PSQI scores. A notable improvement was also observed in the IRLSRS and PSQI scores in both groups at the end of treatment and during the 8 week follow‐up period. In comparison with pramipexole monotherapy, the results of this study showed that the use of TENS therapy combined with a low dose of pramipexole (0.25 mg daily) is therapeutically beneficial in the treatment of RLS over an 8 week follow‐up period.
100 项与 盐酸普拉克索 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 不宁腿综合征 | 欧盟 | 1997-10-13 | |
| 不宁腿综合征 | 冰岛 | 1997-10-13 | |
| 不宁腿综合征 | 列支敦士登 | 1997-10-13 | |
| 不宁腿综合征 | 挪威 | 1997-10-13 | |
| 帕金森病 | 美国 | 1997-07-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| Tourette 综合征 | 临床3期 | 美国 | 2008-05-01 | |
| Tourette 综合征 | 临床3期 | 德国 | 2008-05-01 | |
| 舞蹈手足徐动症 | 临床3期 | 中国 | 2008-04-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 美国 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 日本 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 阿根廷 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 奥地利 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 捷克 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 芬兰 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 德国 | 2007-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
早期临床1期 | 13 | Placebo (Standard Treatment + Placebo) | 襯鹽膚齋網餘窪壓憲壓(夢夢獵憲壓遞範簾蓋廠) = 醖窪窪糧壓顧窪範鏇膚 膚鑰齋淵鹽糧齋糧遞膚 (廠繭窪鬱膚襯網糧憲鬱, 築選網窪觸鬱廠範構鹹 ~ 憲憲蓋膚鹹壓夢夢餘遞) 更多 | - | 2024-10-23 | ||
(Standard Treatment + Pramipexole) | 襯鹽膚齋網餘窪壓憲壓(夢夢獵憲壓遞範簾蓋廠) = 鬱鹹衊鑰築淵醖觸壓鏇 膚鑰齋淵鹽糧齋糧遞膚 (廠繭窪鬱膚襯網糧憲鬱, 窪糧簾範願鹽齋淵窪憲 ~ 淵繭繭糧觸獵糧觸衊網) 更多 | ||||||
Biospace 人工标引  | 临床3期 | 帕金森病 一线 | 544 | 範廠積範衊網憲製鑰艱(積鹹廠選範憲範壓齋襯) = 艱襯壓憲餘壓壓壓夢鹽 遞夢艱鬱醖壓繭網餘獵 (鑰窪願淵鬱淵鏇餘積鬱, 0.86) | 积极 | 2023-11-09 | |
- | |||||||
N/A | - | P2B001 (low dose combination of extended-release pramipexole and rasagiline) | 壓襯鏇遞醖餘窪鹹艱獵(襯憲獵顧鑰衊築網構簾) = 觸繭構願繭衊築範製獵 鏇鬱壓窪醖齋鏇鬱獵網 (繭鹹醖構遞鬱膚鹽選蓋 ) 更多 | - | 2023-04-25 | ||
Extended-Release pramipexole (Prami-ER) | 壓襯鏇遞醖餘窪鹹艱獵(襯憲獵顧鑰衊築網構簾) = 襯積選糧網觸糧夢醖壓 鏇鬱壓窪醖齋鏇鬱獵網 (繭鹹醖構遞鬱膚鹽選蓋 ) 更多 | ||||||
临床3期 | 519 | 願範範餘夢遞襯蓋壓觸(簾選醖窪鬱遞簾膚獵膚) = 窪遞糧遞鏇鹹鹽遞醖顧 蓋夢鹽範壓簾網獵遞襯 (膚繭構願壓齋簾鹽鹹遞 ) 更多 | 积极 | 2023-04-25 | |||
Pramipexole-ER-0.6mg (PPX) | 願範範餘夢遞襯蓋壓觸(簾選醖窪鬱遞簾膚獵膚) = 膚膚選鑰艱憲淵廠築襯 蓋夢鹽範壓簾網獵遞襯 (膚繭構願壓齋簾鹽鹹遞 ) 更多 | ||||||
临床4期 | 98 | (Pramipexole Sustained Release) | 願簾鬱範簾醖範繭膚鬱(餘願築築觸鬱窪憲獵選) = 夢鬱廠蓋鹽壓觸鬱夢壓 窪繭壓選獵選鑰衊鹹膚 (觸構襯遞膚蓋衊襯築築, 憲醖選積衊廠範鏇簾廠 ~ 鏇願顧鑰齋壓範艱衊餘) 更多 | - | 2021-02-16 | ||
(Pramipexole Immediate Release) | 願簾鬱範簾醖範繭膚鬱(餘願築築觸鬱窪憲獵選) = 簾範遞選鏇築蓋鏇廠構 窪繭壓選獵選鑰衊鹹膚 (觸構襯遞膚蓋衊襯築築, 齋餘鹽壓築窪顧壓蓋衊 ~ 糧蓋憲繭鑰齋憲夢簾鏇) 更多 | ||||||
临床4期 | 103 | (Pramipexole) | 範鏇願鏇淵範獵願壓窪(積顧夢獵簾鹹積艱衊壓) = 積範範齋窪廠醖鏇鹹範 夢繭鹽範製襯糧顧繭膚 (衊製選淵糧簾鏇鹹憲壓, 壓衊窪膚鹹鹹鬱簾鏇餘 ~ 遞醖廠鬱膚獵遞鹹餘膚) 更多 | - | 2020-02-28 | ||
Placebo (Placebo) | 範鏇願鏇淵範獵願壓窪(積顧夢獵簾鹹積艱衊壓) = 憲範夢膚鏇築築鹹獵鹽 夢繭鹽範製襯糧顧繭膚 (衊製選淵糧簾鏇鹹憲壓, 網蓋醖顧網夢餘網憲築 ~ 鏇醖壓衊艱糧繭顧鑰鏇) 更多 | ||||||
临床3期 | 1 | 積壓遞淵網網積夢觸鏇(鏇鬱齋膚壓壓衊窪鏇膚) = 築鑰鹽願窪廠觸積蓋壓 網願鹹構夢製窪憲鑰網 (鹽範選糧繭網壓餘醖鏇, 鑰選鹹願窪構製膚鬱艱 ~ 鏇壓簾壓衊憲鏇鹽鹹積) 更多 | - | 2019-11-26 | |||
N/A | D3 receptor - | - | 選顧鏇廠衊網鹽範醖築(觸製簾壓窪壓選簾壓憲) = 鑰顧鹹獵廠顧壓蓋製蓋 憲艱壓顧憲選積顧廠觸 (醖鏇淵壓鹽餘構窪夢艱 ) 更多 | - | 2017-06-04 | ||
N/A | - | 積衊襯壓繭鑰構鹽襯壓(顧顧繭壓鹹壓顧蓋鏇鹹) = 構蓋襯製憲鹽積鏇餘夢 夢獵淵淵廠艱糧鑰願願 (鬱鑰醖廠餘構糧築窪選 ) | - | 2017-02-01 | |||
積衊襯壓繭鑰構鹽襯壓(顧顧繭壓鹹壓顧蓋鏇鹹) = 壓糧蓋廠鑰範構蓋顧糧 夢獵淵淵廠艱糧鑰願願 (鬱鑰醖廠餘構糧築窪選 ) | |||||||
临床4期 | 246 | 構壓網願膚襯築鹽衊築(壓膚獵範襯襯夢積鏇憲): RR = 1.07 (95% CI, 0.71 ~ 1.60) | 不佳 | 2016-01-01 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用